Compass Therapeutics (NASDAQ:CMPX) Upgraded at Leerink Partners

Leerink Partners upgraded shares of Compass Therapeutics (NASDAQ:CMPX) from a market perform rating to an outperform rating in a report published on Wednesday, MarketBeat Ratings reports. The firm currently has $6.00 target price on the stock, up from their prior target price of $4.00.

Several other research analysts also recently weighed in on the stock. Jefferies Financial Group upped their target price on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, February 10th. Piper Sandler initiated coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price objective for the company. D. Boral Capital restated a “buy” rating and set a $32.00 target price on shares of Compass Therapeutics in a research note on Tuesday. Guggenheim started coverage on Compass Therapeutics in a research note on Monday, February 24th. They issued a “buy” rating and a $12.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a report on Wednesday, January 8th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Compass Therapeutics currently has an average rating of “Buy” and an average target price of $13.38.

Compass Therapeutics Price Performance

Shares of CMPX opened at $1.46 on Wednesday. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $4.08. The stock’s 50-day moving average is $2.76 and its two-hundred day moving average is $2.10. The stock has a market cap of $201.89 million, a PE ratio of -3.95 and a beta of 1.19.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, research analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Trading of Compass Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Intech Investment Management LLC bought a new stake in shares of Compass Therapeutics in the 3rd quarter valued at approximately $30,000. Tower Research Capital LLC TRC lifted its position in shares of Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after buying an additional 12,917 shares during the last quarter. Independent Advisor Alliance acquired a new position in shares of Compass Therapeutics in the 4th quarter valued at about $26,000. BNP Paribas Financial Markets bought a new stake in shares of Compass Therapeutics during the 4th quarter valued at about $27,000. Finally, XTX Topco Ltd acquired a new stake in Compass Therapeutics during the third quarter worth about $37,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.